Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 6/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21882365 | 0.82 | ATF4 (0.55) | ATF4SCN9AHTR7 | |
| SCHEMBL22362344 | 0.81 | KDM4E (0.50) | — | |
| SCHEMBL22373942 | 0.80 | ATF4 (0.44) | ATF4USP30 | |
| SCHEMBL22362324 | 0.79 | SCN9A (0.47) | SCN9A | |
| SCHEMBL21882369 | 0.79 | ATF4 (0.54) | ATF4SCN9AMAPTL3MBTL1 | |
| SCHEMBL22777603 | 0.79 | KDM4E (0.57) | — | |
| Trifluoroacetic Acid SCHEMBL22777505 | 0.77 | CHRM1 (0.48) | SCN9A | |
| Trifluoroacetic Acid SCHEMBL22362322 | 0.76 | SCN9A (0.47) | ATF4SCN9A | |
| Trifluoroacetic Acid SCHEMBL22362258 | 0.76 | SCN9A (0.42) | ATF4SCN9AHTR7 | |
| Trifluoroacetic Acid SCHEMBL22362286 | 0.76 | SCN9A (0.50) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270232-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270232-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | ATF4 1/4885SCN9A 4611/4885USP30 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.